Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Current treatment options and standard of care
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

12 evidence topics · 10 sources

Sodium channel blockers4 evidence topics · 4 sources
Benzodiazepines1 evidence topic · 1 source
Other antiseizure medications1 evidence topic · 1 source
Corticosteroids and immunoglobulins1 evidence topic · 1 source
Ketogenic dietary therapy1 evidence topic · 1 source
Vagus nerve stimulation1 evidence topic · 1 source
Cannabinoids1 evidence topic · 1 source
Developmental and supportive therapies1 evidence topic · 1 source
Limitations of current therapies1 evidence topic · 5 sources